COMBAT-COVID

In mechanically ventilated patients with COVID-19 and severe endotheliopathy, does prostacylin compared with placebo, improve days alive without ventilation by day 28?
Continue reading »A compendium of critical appraisals in Intensive Care Medicine research and related specialties
In mechanically ventilated patients with COVID-19 and severe endotheliopathy, does prostacylin compared with placebo, improve days alive without ventilation by day 28?
Continue reading »Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial @PeterHorby. medRxiv pre-print 2021 doi: https://doi.org/10.1101/2021.06.15.21258542 Clinical Question In hospitalised patients with COVID-19, does the addition of monoclonal antibodies REGEN-COV (carsirivimab & imdevimab) to standard care, compared with standard care alone, improve 28 day mortality? Background Monoclonal antibodies have been shown to be […]
Continue reading »In patients with severe COVID, does 12mg dexamethasone vs 6mg dexamethasone increase the number of days alive without life support at 28 days?
Continue reading »In hospitalised adult patient with COVID-19, does baricitinib compared with placebo decrease a composite outcome of progression of illness and mortality?
Continue reading »In hospitalised patients with COVID-19 requiring >40% FiO2 to achieve SaO2>94%, does the use of continuous positive airway pressure (CPAP) or high flow nasal oxygen (HFNO) compared with conventional O2 therapy (COT) reduce the incidence of tracheal intubation or death within 30 days?
Continue reading »Treatment of Multisystem Inflammatory Syndrome in Children McArdle. NEJM 2021; 385: 35-45.DOI: 10.1056/NEJMoa2102968 Clinical Question In children with multisystem inflammatory syndrome, what affect do different treatments have on the composite of inotropic support or mechanical ventilation by day 2 or death, and disease severity by day 2? Background Multisystem inflammatory syndrome in children (MIS-C) is a new, rare but serious […]
Continue reading »In hospitalised adult patients with severe or critical COVID-19 pneumonia, does tocilizumab plus standard care compared with standard care alone, improve clinical outcomes at day 15?
Continue reading »es convalescent plasma compared with placebo, improve patients’ clinical status at 30 days?
Continue reading »In critically ill patients with COVID-19, do the IL-6 receptor antagonists, tocilizumab and sarilumab, compared with standard care, improve respiratory and cardiovascular organ support free days up to day 21?
Continue reading »In hospitalised patients with severe acute respiratory syndrome due to coronavirus 2 (SAR-CoV-2), does tocilizumab compared with placebo, reduce intubation rates or mortality?
Continue reading »